Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Partner
Lundbeckfond Ventures - Copenhagen, Denmark
Sr. Manager E Business Job
Celgene Corporation - Summit, NJ, US
Associate Director Global Market Research Job
Celgene Corporation - Summit, NJ, US
Coordinator, Documentation Job
Celgene Corporation - Ruby St, IL, US
Scientist/Sr. Scientist, Bio-analytical Chemistry
Dicerna Pharmaceuticals, Inc. - Watertown, MA

More Jobs >>

Events

8th Annual Columbia Business School Healthcare Conference
Oct 28 — New York
Master's Degree in Molecular Biotechnology
Health Market Science Webinar: 3 Steps to New Physician Opportunities
Nov. 17
Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston

More Events >>

Related Tags >> cancer vaccine Generex Development deals therapeutic vaccines

Pevion Biotech News

Most Popular Pevion Biotech Story

PEV7 - 10 promising therapeutic vaccines

October 26, 2011 — 4:06pm ET

Vaccine: PEV7Company: Pevion BiotechTarget: Recurrent vulvovaginal candidiasis Good news for women who suffer from chronic yeast infections, alias thrush, alias recurrent vulvovaginal candidiasis Read more...

Pevion Biotech Press Releases

Pevion Biotech's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity
Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing
Generex Biotechnology and Pevion Biotech Announce Plans for Immunotherapeutic Vaccine Collaboration

Latest Headlines

PEV7 - 10 promising therapeutic vaccines
October 26, 2011
Generex, Pevion team up on cancer vaccines
December 18, 2008

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK